Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

2(40%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

60%

Ph phase_4

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 3Large-scale testing

3(60.0%)

Phase 4Post-market surveillance

2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(2)

Other(1)

Detailed Status

Active, not recruiting2

Completed2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 33 (60.0%)

Phase 42 (40.0%)

Trials by Status

active_not_recruiting240%

completed240%

unknown120%

Recent Activity

2 active trials

Showing 5 of 5

active_not_recruitingphase_3

Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume

NCT05701332

completedphase_3

Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)

NCT02795260

Clinical Trials (5)

Showing 5 of 5 trials

NCT05538663Phase 3

Intravesical BCG vs GEMDOCE in NMIBC

Active Not Recruiting

NCT04701151Phase 4

NORTH-REG Dwell-Time Study

Active Not Recruiting

NCT04806178Phase 3

Immunological Response of Bladder Cancer Patients Under BCG

Completed

NCT05701332Phase 4

Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume

Unknown

NCT02795260Phase 3

Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5